Eva Pokorna
Prague, PR 12853, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas.
Journal: Scientific reports
Published: February 13, 2026
Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: March 12, 2025
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
Journal: Leukemia
Published: February 23, 2024
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Journal: Experimental hematology & oncology
Published: September 01, 2023
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas.
Journal: Laboratory investigation; a journal of technical methods and pathology
Published: February 26, 2022
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.
Journal: Molecular cancer therapeutics
Published: June 09, 2021
Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma.
Journal: Acta biomaterialia
Published: August 19, 2020
Quantitative In Vivo Monitoring of Hypoxia and Vascularization of Patient-Derived Murine Xenografts of Mantle Cell Lymphoma Using Photoacoustic and Ultrasound Imaging.
Journal: Ultrasound in medicine & biology
Published: August 06, 2020
Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: June 16, 2020
Last Updated: 09/26/2026